The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.

Safety:AE/SAE Efficacy:immunologic function;FPS

Inclusion Criteria:

• Aged between 18 to 80 years, males and females.
• Subjects who understand and sign the consent form for this study.
• The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes.
• Subjects are surgical candidates.
• No distant metastasis (M0) and No distant lymph node metastasis.
• Expected survival time of at least 6 months.

Exclusion Criteria:

• Subjects who do not sign the consent form for this study.
• The subject has an allergic history of medicine or food.
• The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system.
• The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases.
• The subject has an history of other malignant tumour.
• The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial.
• The subject has participated in any other clinical trial in the 3 months prior to this trial.
• The subject is pregnant, lactating or planning to conceive within the next 24 months.
• The subject has any other unsuitable or adverse condition to be determined by the investigator.